Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
Open Access
- 16 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 22 (3), 209-216
- https://doi.org/10.1093/protein/gzn055
Abstract
We have previously demonstrated preclinical in vivo targeting of prostate stem cell antigen (PSCA) using a humanized anti-PSCA 2B3 monoclonal antibody (mAb). However, humanization resulted in 5-fold loss of apparent affinity relative to the parental mAb (1 nM). In this study, diabodies (scFv dimers of 55 kDa) were generated from 2B3 including variants with different linker lengths as well as back-mutations to original murine residues to improve affinity. Parental 2B3 (p2B3) and back-mutated 2B3 (bm2B3) diabodies (Dbs) with five- or eight-amino acid linkers (p2B3-Db5, p2B3-Db8, bm2B3-Db5 and bm2B3-Db8) were evaluated for binding to PSCA by flow cytometry and affinities were determined by surface plasmon resonance. Back-mutation restored the affinity from 5.4 to 1.9 nM. Stability, evaluated by size exclusion, revealed that diabodies with eight-residue linkers existed as a mixture of dimeric and monomeric species at low concentrations (≤1 mg/ml). Shortening the linker from eight to five residues improved dimer stability, notably in the bm2B3-Db8 compared with bm2B3-Db5. Both p2B3-Db8 and bm2B3-Db8 were radioiodinated with 124I and evaluated by serial micro-positron emission tomography imaging in mice bearing LAPC-9 human prostate cancer xenografts. Localization in LAPC-9 xenografts was seen at 4 h, whereas at 20 h most of the activity had cleared from the tumor. Highest tumor-to-background contrast ratios and best images were obtained at 12 h. Although the higher affinity bm2B3-Db8 demonstrated improved tumor retention at later time points (20 h), it did not improve tumor targeting or imaging compared with p2B3-Db8 at 12 h.Keywords
This publication has 41 references indexed in Scilit:
- Tumor Targeting by a Multivalent Single-Chain Fv (scFv) Anti-Lewis Y Antibody ConstructCancer Biotherapy & Radiopharmaceuticals, 2008
- Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv DimersClinical Cancer Research, 2006
- Identification of a Novel Prostate Tumor Target, Mindin/RG-1, for Antibody-Based Radiotherapy of Prostate CancerCancer Research, 2005
- A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targetingBiochemical and Biophysical Research Communications, 2005
- Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 DiabodyCancer Research, 2005
- Antigen binding and stability properties of non‐covalently linked anti‐CD22 single‐chain Fv dimersFEBS Letters, 2004
- Immunosuppressive properties of anti-CD3 single-chain Fv and diabodyJournal of Immunological Methods, 2003
- Expression and functional analysis of recombinant scFv and diabody fragments with specificity for human RhDJournal of Molecular Recognition, 2002
- Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered AntibodiesCancer Biotherapy & Radiopharmaceuticals, 2001
- Crystal structure of a diabody, a bivalent antibody fragmentStructure, 1994